AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22491731 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3
Number of subjects: 61
Study 22491798 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and trientine
Number of subjects: 5
Study 22491916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ketorolac (4 mg)
Number of subjects: 10
Study 22491953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective mechanical ventilation (adherence measured by ventilator settings)
Number of subjects: 485
Study 22491953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective mechanical ventilation (50% adherence)
Number of subjects: 485
Study 22491953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective mechanical ventilation (100% adherence)
Number of subjects: 485
Study 22493293 — intervention group
Group type: EXPERIMENTAL
Intervention: First salvage chemotherapy (n = 224)
Number of subjects: 547
Study 22493293 — intervention group
Group type: EXPERIMENTAL
Intervention: Second salvage chemotherapy (n = 82)
Number of subjects: 547
Study 22493293 — intervention group
Group type: EXPERIMENTAL
Intervention: First salvage chemotherapy after relapse post-SCT (n = 48)
Number of subjects: 547
Study 22493293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival after relapse
Number of subjects: 547
Study 22493293 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of stem cell transplantation (SCT)
Number of subjects: 547
Study 22493299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide in combination with weekly dexamethasone (Pom/dex)
Number of subjects: 33
Study 22494019 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 125
Study 22494019 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 22494428 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-care management program
Number of subjects: 3296
Study 22494428 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-care management program (pharmacotherapy and combination trials)
Number of subjects: 3296
Study 22494428 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-care management program (psychotherapy and combination trials)
Number of subjects: 3296
Study 22494861 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial infarction (PMI)
Number of subjects: 1188
Study 22494861 — intervention group
Group type: EXPERIMENTAL
Intervention: PMI
Number of subjects: 1188
Study 22496496 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (25 mg iv infusion)
Number of subjects: 16
Study 22497915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0·12% chlorhexidine digluconate
Number of subjects: 74
Study 22497915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral care without antiseptic)
Number of subjects: 74
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to chemotherapy
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG PS 0
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Asians
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastases to one site
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (<65 years)
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG PS
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Region
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor histology
Number of subjects: 1125
Study 22498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of organs involved
Number of subjects: 1125
Study 22499072 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 36
Study 22499072 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 36
Study 22499072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pCLE and NBI
Number of subjects: 36
Study 22499613 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-RGD-K5
Number of subjects: 7
Study 22499837 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with lower and higher doses of pyrimethamine with sulfadizine
Number of subjects: 193
Study 22499837 — intervention group
Group type: EXPERIMENTAL
Intervention: NE-II serotype
Number of subjects: 193
Study 22499837 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II and NE-II infections
Number of subjects: 193
Study 22500948 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 4
Study 22500948 — intervention group
Group type: COMPARATOR
Intervention: Placebo/active comparator
Number of subjects: 4
Study 22503162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75-300 mg BID)
Number of subjects: 1206
Study 22503160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey Auditory Verbal Learning Task total in CN subjects at 36 months
Number of subjects: 499
Study 22503160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating scale sum of boxes in MCI
Number of subjects: 499
Study 22503395 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 707
Study 22503395 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery treatment (PST)
Number of subjects: 707
Study 22503395 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT responders
Number of subjects: 707
Study 22503395 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT in stage IB2
Number of subjects: 707
Study 22503395 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT for patients with stage IB tumours of 2-5 cm
Number of subjects: 707
Study 22503658 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 745
Study 22503658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 22504925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, cyclophosphamide, and dexamethasone (CRd)
Number of subjects: 35
Study 22504934 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab tiuxetan at two dose levels (22 and 30 MBq/kg) combined with reduced intensity conditioning (RIC) using fludarabine, melphalan, and alemtuzumab followed by allogeneic hematopoietic cell transplantation (HCT).
Number of subjects: 20
Study 22506003 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR patients after ROSC
Number of subjects: 17
Study 22506003 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 17
Study 22506003 — intervention group
Group type: COMPARATOR
Intervention: Patients after cardiac surgery
Number of subjects: 17
Study 22506003 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR patients after ROSC (6 hours post-admission)
Number of subjects: 17
Study 22506003 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR patients after ROSC (subsequent time points)
Number of subjects: 17
Study 22506623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 or 10 mg once daily
Number of subjects: 21
Study 22506949 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of EFIC regulations in the RAMPART trial
Number of subjects: 0
Study 22507624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-308 GA genotype
Number of subjects: 490
Study 22507624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-863 CA genotype
Number of subjects: 490
Study 22507624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-863 A carrier status
Number of subjects: 490
Study 22508412 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of a monovalent pediatric HBV vaccine (10 μg of HBsAg)
Number of subjects: 0
Study 22508715 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 15
Study 22508772 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 20 mg twice daily
Number of subjects: 16
Study 22508772 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 16
Study 22508772 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast (both doses)
Number of subjects: 16
Study 22508812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline-taxane-based chemotherapy
Number of subjects: 6377
Study 22508956 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention involving an interview about rehabilitation needs with a rehabilitation coordinator, information from the hospital to the GP about individual needs for rehabilitation, and encouragement for the GP to contact the patient.
Number of subjects: 955
Study 22508956 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual procedures)
Number of subjects: 955
Study 22508957 — intervention group
Group type: EXPERIMENTAL
Intervention: Online adverts for CBT
Number of subjects: 3868
Study 22508957 — intervention group
Group type: COMPARATOR
Intervention: No adverts for CBT
Number of subjects: 3868
Study 22509296 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU eligibility as assessed by ED and ICU physicians
Number of subjects: 2646
Study 22509296 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 2646
Study 22509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month mortality
Number of subjects: 2646
Study 22509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status at six months
Number of subjects: 2646
Study 22509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability of ICU eligibility rates
Number of subjects: 2646
Study 22509296 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between ICU eligibility and outcomes
Number of subjects: 2646
Study 22509859 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 30)
Number of subjects: 0
Study 22510871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg IV every 3 weeks, median 8 cycles; range, 1-16)
Number of subjects: 25
Study 22510871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 25
Study 22511402 — intervention group
Group type: EXPERIMENTAL
Intervention: RX Herculink Elite Renal Stent System (Abbott Vascular)
Number of subjects: 202
Study 22511404 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE grafts for MHV reconstruction
Number of subjects: 262
Study 22511404 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved iliac veins
Number of subjects: 262
Study 22511404 — intervention group
Group type: COMPARATOR
Intervention: Iliac arteries
Number of subjects: 262
Study 22511404 — intervention group
Group type: COMPARATOR
Intervention: Aortas
Number of subjects: 262
Study 22511404 — intervention group
Group type: COMPARATOR
Intervention: Vein segment 5
Number of subjects: 262
Study 22511492 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide/dexamethasone treatment after nine cycles
Number of subjects: 47
Study 22511492 — intervention group
Group type: COMPARATOR
Intervention: baseline (before treatment)
Number of subjects: 47
Study 22511498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, fludarabine and mitoxantrone followed by 2-monthly rituximab maintenance
Number of subjects: 29
Study 22511498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 29
Study 22511498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab pharmacokinetics
Number of subjects: 29
Study 22511498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab C(trough)
Number of subjects: 29
Study 22512824 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein
Number of subjects: 16
Study 22512824 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 16
Study 22512824 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 16
Study 22512844 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy using high-intensity focused ultrasound delivered to all known cancer lesions with a margin of normal tissue.
Number of subjects: 42
Study 22514241 — intervention group
Group type: EXPERIMENTAL
Intervention: Male subjects
Number of subjects: 737
Study 22514241 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 737
Study 22514241 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for male subjects
Number of subjects: 737
Study 22514241 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for female subjects
Number of subjects: 737
Study 22514617 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT-positive children treated with ACT
Number of subjects: 391
Study 22514617 — intervention group
Group type: COMPARATOR
Intervention: RDT-negative children (non-malaria)
Number of subjects: 391
Study 22515681 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 40
Study 22515800 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections at 1, 5, and 9 weeks, with as-needed treatments at weeks 13 and 17.
Number of subjects: 36
Study 22515800 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections.
Number of subjects: 36
Study 22515800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose opioid analgesia for procedure-related pain.
Number of subjects: 36
Study 22515800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy.
Number of subjects: 36
Study 22516251 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (ER)
Number of subjects: 291
Study 22516395 — intervention group
Group type: EXPERIMENTAL
Intervention: New crossing catheter and re-entry system
Number of subjects: 147
Study 22516397 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR measurement in MV ostial lesions
Number of subjects: 93
Study 22516397 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR measurement in SB ostial lesions
Number of subjects: 93
Study 22516401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 28
Study 22516441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 0
Study 22517196 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper version of ICIQ-LUTSqol (n=78)
Number of subjects: 132
Study 22517196 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based version of ICIQ-LUTSqol (n=54)
Number of subjects: 132
Study 22517196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both paper and web-based versions
Number of subjects: 132
Study 22517904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d (RdC)
Number of subjects: 37
Study 22518187 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal music exposure (listening to a pre-recorded music cassette for approximately 1 hour/day in addition to standard antenatal care)
Number of subjects: 260
Study 22518187 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control arm)
Number of subjects: 260
Study 22518187 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal music exposure
Number of subjects: 260
Study 22520270 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFerade biologic (5 weekly injections, dose-escalated from 4 × 10(8) to 4 × 10(11) PU) combined with chemoradiotherapy (cisplatin 75 mg/m(2), 5-fluorouracil 1000 mg/m(2)/d for 96 hours, radiation therapy to 45 Gy)
Number of subjects: 24
Study 22520270 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFerade biologic with chemoradiotherapy
Number of subjects: 24
Study 22520529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound analysis of plaque distribution in LAD
Number of subjects: 136
Study 22520529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound analysis of plaque distribution in RCA
Number of subjects: 136
Study 22520686 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH PET/CT
Number of subjects: 210
Study 22520945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (30-75 mg once daily for 6 weeks)
Number of subjects: 49
Study 22520945 — intervention group
Group type: COMPARATOR
Intervention: Pooled safety data from treatment studies (duration of 5 days) in children
Number of subjects: 49
Study 22522212 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT2 gene SNP rs2896218
Number of subjects: 373
Study 22522212 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-locus haplotype in the WNT2 gene
Number of subjects: 373
Study 22522212 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction effect between SNP rs2228946 in WNT2 and SNP rs6460013 in EN2
Number of subjects: 373
Study 22522612 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion during exercise (N+)
Number of subjects: 8
Study 22522612 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion during exercise (N-)
Number of subjects: 8
Study 22522612 — intervention group
Group type: COMPARATOR
Intervention: Naloxone infusion without exercise (control)
Number of subjects: 8
Study 22522617 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 0
Study 22522617 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenin-25
Number of subjects: 0
Study 22522617 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP plus Xenin-25
Number of subjects: 0
Study 22522617 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study 22523054 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital events; cardiovascular events, hospital admissions and mortality during follow-up.
Number of subjects: 4169
Study 22523260 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline for 15 days
Number of subjects: 117
Study 22523260 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline for 10 days
Number of subjects: 117
Study 22523260 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with erythema migrans
Number of subjects: 117
Study 22523260 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without a history of Lyme borreliosis
Number of subjects: 117
Study 22523360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) during noninvasive ventilation (NIV) without leaks
Number of subjects: 21
Study 22523360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) during noninvasive ventilation (NIV) with induced leaks
Number of subjects: 21
Study 22523360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) compared to oesophageal pressure (P(oes))
Number of subjects: 21
Study 22523360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) during nocturnal NIV in OHS patients
Number of subjects: 21
Study 22523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obstructive sleep apnoea/hypopnoea (OSAH) defined by an apnoea/hypopnoea index (AHI) >30 · h(-1) (17% of subjects)
Number of subjects: 470
Study 22523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSAH (AHI 15-30)
Number of subjects: 470
Study 22523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSAH
Number of subjects: 470
Study 22523363 — intervention group
Group type: EXPERIMENTAL
Intervention: SRBD severity expressed using ODI >10 · h(-1)
Number of subjects: 470
Study 22524591 — intervention group
Group type: EXPERIMENTAL
Intervention: TExT-MED program (text message-based intervention, 3 messages daily for 3 weeks)
Number of subjects: 23
Study 22524974 — intervention group
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Number of subjects: 14
Study 22525392 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkali-treated penicillin G
Number of subjects: 68
Study 22525392 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G sodium (PGs)
Number of subjects: 68
Study 22525392 — intervention group
Group type: COMPARATOR
Intervention: Commercial reagents (PPL + DAP-MDM)
Number of subjects: 68
Study 22525883 — intervention group
Group type: EXPERIMENTAL
Intervention: certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks up to week 52
Number of subjects: 89
Study 22526363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy-Flu-ATG
Number of subjects: 83
Study 22526363 — intervention group
Group type: COMPARATOR
Intervention: Cy-ATG
Number of subjects: 83
Study 22527084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised drug labelling used hospital-wide
Number of subjects: 482
Study 22527084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised drug labelling used in ICU
Number of subjects: 482
Study 22527084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised drug labelling by region
Number of subjects: 482
Study 22527084 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ISO 26825 norm
Number of subjects: 482
Study 22527084 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for ISO 26825 norm labelling from pharmaceutical industry
Number of subjects: 482
Study 22527314 — intervention group
Group type: EXPERIMENTAL
Intervention: FUSION regimen (ranibizumab)
Number of subjects: 17
Study 22528284 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DARB) 1 mg/kg IV immediately before surgery
Number of subjects: 18
Study 22528284 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 18
Study 22528284 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DARB)
Number of subjects: 18
Study 22529239 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0